INmune Bio Granted Phase I Clinical Trial Authorization of Lead Product INKmune™ in Refractory and...

Trastuzumab-Resistant HER2 Positive Breast Cancer Reversed By Treatment with INB03...

INmune Bio Announces Publication of Myeloid-Derived Suppressor Cells (MDSC) Report in the Cell’s T...

INmune Nominated for Buzz of Bio Award at 2019 CEO & Investor Conference -Voting begins today: ...

Data from University of Pittsburgh on INB03TM for Treatment of Melanoma Presented at the 33rd Annual...

INmune Bio to Present at National Investment Banking Association Conference ...

INmune Bio Co-Founder and CSO Named Regional VP to the Board of International Society of Cell and Ge...

INmune Bio Named Finalist for Lifestars’ U.S. Private Company of the Year Award...

INmune Bio Co-Founder and Chief Scientific Officer Mark Lowdell, Ph.D., Chairing Sessions at Interna...

INmune Bio to Present at Two Prestigious Cambridge Healthtech Institute Events...

INmune Bio CEO Dr. Raymond J. Tesi to Present at 14th Annual Biomarkers & Immuno-Oncology World ...

INmune Bio Initiates Phase I Clinical Trial of INB03...

INmune Bio’s Professor Mark Lowdell to Participate as Expert Speaker at the Third Annual Innate Ki...

INmune Bio Appoints Scott Juda to Board of Directors...

INmune Bio to Present at Upcoming Conferences...

INmune Bio presenting at NobleCon14 on January 29th ...